bluebird bio Garners $60,000,000 Series D Funding Round

  • Feed Type
  • Date
    7/25/2012
  • Company Name
    bluebird bio
  • Mailing Address
    840 Memorial Drive Cambridge, MA 02139
  • Company Description
    bluebird bio is developing innovative gene therapies for severe genetic disorders. At the heart of bluebird bio’s product creation efforts is its broadly applicable gene therapy platform for the development of novel treatments for diseases with few or no clinical options.
  • Website
    http://www.bluebirdbio.com
  • Transaction Type
    Venture Equity
  • Transaction Amount
    $60,000,000
  • Transaction Round
    Series D
  • Proceeds Purposes
    Proceeds will be used to advance the company’s clinical programs in severe genetic disorders, including childhood cerebral adrenoleukodystrophy (CCALD), beta-thalassemia and sickle cell disease.
  • M&A Terms
  • Venture Investor
    Deerfield Capital
  • Venture Investor
    RA Capital
  • Venture Investor
    Shire Pharmaceuticals
  • Venture Investor
    Undisclosed

By posting a comment, you agree to our terms and conditions.